![](https://medcitynews.com/wp-content/uploads/sites/7/2016/11/GettyImages-490025288.jpg)
EQRx’s Affordable Drugs Strategy Ends in Acquisition by Revolution, Interested Only in Its Cash
Revolution Medicines is acquiring EQRx in an all-stock deal bringing that company’s more than $1 billion in cash. It marks the end for EQRx, a company that aimed to develop and commercialize lower-cost drugs for cancer and other diseases.